In fact, studies in multiple myeloma cells indicate that HHT potentiates bortezomib activity through multiple mechanisms, including MCL-1 down-regulation and interference with stromal cell factors, among others [20]. The gene discussed is MCL1; the disease is plasma cell myeloma.